2026-05-17T05:43:34Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/134232024-09-27T09:23:37Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Lareo, Ana author Nuche, Jorge author Cristo Ropero, Maria J author Arribas-Ynsaurriaga, Fernando author Oliver, Eduardo author Escribano-Subias, Pilar author 2021-04 Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary vascular remodeling leading to increased vascular resistance. The increased afterload contributes to the development of right ventricular dysfunction and heart failure, which is the leading cause of death among patients with PAH. The development of specific treatments has markedly improved the prognosis of this population. However, PAH continues to be an incurable, life‑limiting condition, which creates a major burden for healthcare systems. This review describes the currently used treatments for PAH and provides insight into novel therapeutic targets that aim to reduce vascular remodeling, which ultimately leads to right ventricular failure. Kardiol Pol. 2021; 79(4):386-392 10.33963/KP.15928 1897-4279 Kardiologia polska 33843179 http://hdl.handle.net/20.500.12105/13423 Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations.